Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.71 |
| ▸ | USP1 | O94782 | 6/20 | 0.71 |
| ▸ | WDR48 | Q8TAF3 | 6/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | PDE5A | O76074 | 3/20 | 0.68 |
| ▸ | GBA1 | P04062 | 2/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1083888 | 0.85 | MAPK1 (0.73) | MAPK1MAPTPOLBMEN1KMT2A | |
| SCHEMBL1084178 | 0.84 | MAPT (0.73) | MAPK1MAPTPOLBMEN1KMT2A | |
| SCHEMBL28805460 | 0.83 | CYP1A2 (0.80) | MAPK1MAPTPOLBMEN1KMT2A | |
| SCHEMBL1083779 | 0.83 | CYP1A2 (0.80) | MAPK1MAPTPOLBMEN1KMT2A | |
| SCHEMBL1084041 | 0.83 | KMT2A (1.00) | MAPK1MAPTPOLBMEN1KMT2A | |
| SCHEMBL1083949 | 0.83 | KMT2A (0.71) | MAPK1MAPTPOLBMEN1KMT2A | |
| SCHEMBL2590654 | 0.83 | MAPK1 (0.71) | MAPK1MAPTPOLBMEN1KMT2A | |
| SCHEMBL1084254 | 0.82 | KMT2A (1.00) | MAPK1MAPTPOLBMEN1KMT2A | |
| SCHEMBL1084183 | 0.82 | MEN1 (0.89) | MAPK1MAPTPOLBMEN1KMT2A | |
| SCHEMBL27899412 | 0.82 | USP1 (0.71) | MAPK1MAPTPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865708-B2 | Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865708-B2 | Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-21 | — | — | US | disclosed |
| CN-103068393-A | Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase | CLEAVE BIOSCIENCES INC CLEAVE | 2013-04-24 | — | — | CN | disclosed |
| US-8343980-B2 | Quinazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343980-B2 | Quinazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8153642-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153642-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110288082-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-11-24 | — | — | US | disclosed |
| US-20110288082-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-11-24 | — | — | US | disclosed |
| WO-2011140527-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | CALIFORNIA INSTITUTE OF TECHNOLOGY AND THE UNIVERSITY OF KANSAS (US) | 2011-11-10 | — | — | WO | disclosed |
| US-7713983-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713983-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-11 | — | — | US | disclosed |
| US-7678802-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678802-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288082-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | VCP, PSMG3, PSMB3 | MAPK1 3047/4885MAPT 1557/4885POLB 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.